1-6 of 6
Ulrich Jaeger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 2368: miR-29-TRAF4 axis is a novel regulator of CD40 signaling in malignant B cells

Sonali Sharma, Vaclav Seda, Eva Vojackova, Gabriela Mladonicka Pavlasova, Daniel Filip, Laura Ondrisova, Veronika Sandova, Lenka Kostalova, Pedro F. Zeni, Marek Borsky, Sarka Pospisilova, Medhat Shehata, Laura Z. Rassenti, Ulrich Jaeger, Michael Doubek, Matthew S. Davids, Jennifer R. Brown, Jiri Mayer, Thomas J. Kipps, Marek Mraz
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 2368.
https://doi.org/10.1158/1538-7445.AM2021-2368
Published: 01 July 2021
View article titled, Abstract 2368: <em>miR-29-TRAF4</em> axis is a novel regulator of CD40 signaling in malignant B cells
Journal Articles

Abstract CT162: The phase 1b PORTIA study: Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)

Ulrich Jaeger, Nina Worel, Joseph P. McGuirk, Peter A. Riedell, Isabelle Fleury, Peter Borchmann, Simon Newsome, Ahmed M. Abdelhady, Alessandra Forcina, Lida Bubuteishvili Pacaud, Edmund K. Waller
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT162.
https://doi.org/10.1158/1538-7445.AM2020-CT162
Published: 15 August 2020
View article titled, Abstract CT162: The phase 1b PORTIA study: Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)
Journal Articles

Abstract CT237: Evaluation of in vivo chimeric antigen receptor (CAR) transgene levels in patients (pts) treated with tisagenlecleucel

Rakesh Awasthi, Karen Thudium Mueller, Gregory A. Yanik, Constantine S. Tam, Susana Rives, Joseph P. McGuirk, Michael A. Pulsipher, Michael W. Boyer, Ulrich Jaeger, Andre Baruchel, Gary D. Myers, Peter Borchmann, Stephen J. Schuster, Heather Stefanski, Michael Bishop, Edward R. Waldron, Ozlem Anak, Abhijit Chakraborty, Eric Bleickardt, Stephane Wong, Lida Bubuteishvili Pacaud, Edmund K. Waller, Shannon L. Maude
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT237.
https://doi.org/10.1158/1538-7445.AM2019-CT237
Published: 01 July 2019
View article titled, Abstract CT237: Evaluation of in vivo chimeric antigen receptor (CAR) transgene levels in patients (pts) treated with tisagenlecleucel
Journal Articles

Abstract CT110: Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)

Rakesh Awasthi, Constantine S. Tam, Ulrich Jaeger, Samantha Jaglowski, Stephen Ronan Foley, Koen van Besien, Nina D. Wagner-Johnston, Maria José Kersten, Stephen J. Schuster, Gilles Salles, Richard T. Maziarz, Özlem Anak, Lida Bubuteishvili Pacaud, Lucien Gazi, Edward Waldron, Jason Hamilton, Iulian Pruteanu, Feng Tai, Karen Thudium Mueller, Edmund K. Waller
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT110.
https://doi.org/10.1158/1538-7445.AM2018-CT110
Published: 01 July 2018
View article titled, Abstract CT110: Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
Journal Articles

Abstract CT158: Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Thomas J. Kipps, Graeme Fraser, Steven Coutre, Jennifer R. Brown, Jacqueline C. Barrientos, Paul M. Barr, John C. Byrd, Susan M. O'Brien, Marie-Sarah Dilhuydy, Stephen Devereux, Ulrich Jaeger, Carol Moreno, Paula Cramer, Stephan Stilgenbauer, Asher A. Chanan-Khan, Michelle Mahler, Mariya Salman, Mei Cheng, Anil Londhe, Joi Ninomoto, Angela Howes, Danelle James, Michael Hallek
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT158.
https://doi.org/10.1158/1538-7445.AM2017-CT158
Published: 01 July 2017
View article titled, Abstract CT158: Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Journal Articles

Templated Nucleotide Addition and Immunoglobulin JH-Gene Utilization in t(11;14) Junctions: Implications for the Mechanism of Translocation and the Origin of Mantle Cell Lymphoma

Natascha Welzel, Trang Le, Rodrig Marculescu, Gerlinde Mitterbauer, Andreas Chott, Christiane Pott, Michael Kneba, Ming-Qing Du, Rajko Kusec, Johannes Drach, Markus Raderer, Christine Mannhalter, Klaus Lechner, Bertrand Nadel, Ulrich Jaeger
Journal: Cancer Research
Cancer Res (2001) 61 (4): 1629–1636.
Published: 02 February 2001
View article titled, Templated Nucleotide Addition and Immunoglobulin <em>J</em><sub><em>H</em></sub>-Gene Utilization in t(11;14) Junctions: Implications for the Mechanism of Translocation and the Origin of Mantle Cell Lymphoma
Open the PDF for Templated Nucleotide Addition and Immunoglobulin <em>J</em><sub><em>H</em></sub>-Gene Utilization in t(11;14) Junctions: Implications for the Mechanism of Translocation and the Origin of Mantle Cell Lymphoma in another window